- Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant
Staphylococcus aureusinfections: efficacy and toxicity. Arch Intern Med 2006; 166(19):2138–2144. - Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in
methicillin-resistantStaphylococcus aureusendocarditis. Ann Intern Med 1991; 115(9):674–680. - Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by
bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37(2):281–286. - Conte JE Jr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob
Agents Chemother 2002; 46(5):1475–1480. - Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind
studies of patients with methicillin-resistantStaphylococcus aureusnosocomial pneumonia. Chest
2003; 124(5):1789–1797. - Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-
associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with
vancomycin. Intensive Care Med 2004; 30(3):388–394. - Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant
Staphylococcus aureus. Curr Opin Infect Dis 2004; 17(6):549–555. - Hu J, Yin MT, Furuya EY, et al. Tigecycline outcomes for infections due to multi-drug resistant
Gram-negative organisms. In: ASM, editor. 47th Interscience Conference on Antimicrobial Agents
and Chemotherapy; Chicago, 2007. - Chemaly RF, Hanmod S, Mulanovich V, et al. Tigecycline usage in cancer patients with serious
infections: a report on 110 cases from a single institution. In: ASM, editor. Interscience Conference on
Antimicrobial Agents and Chemotherapy, Washington, D.C., 2008. - Rello J, Mariscal D, March F, et al. RecurrentPseudomonas aeruginosapneumonia in ventilated
patients: relapse or reinfection? Am J Respir Crit Care Med 1998; 157(3 Pt 1):912–916. - Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy forPseudomonas aeruginosabacteremia: outcome
correlations in a prospective study of 200 patients. Am J Med 1989; 87(5):540–546. - Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized
patients: results of a multicenter, randomized, double-blind trial comparing intravenous
ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents
Chemother 1994; 38(3):547–557. - Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem
monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic
patients. Antimicrob Agents Chemother 1994; 38(6):1309–1313. - Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-
aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review
and meta-analysis of randomised trials. BMJ 2004; 328(7441):668. - Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant
Pseudomonas aeruginosawith aerosolized colistin. Am J Respir Crit Care Med 2000; 162(1):328–330. - Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin
for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34(11):
1425–1430. - Rello J, Sole-Violan J, Sa-Borges M, et alet al. Pneumonia caused by oxacillin-resistantStaphylococcus
aureustreated with glycopeptides. Crit Care Med 2005; 33(9):1983–1987. - Palmer LB, Smaldone GC, Simon SR, et al. Aerosolized antibiotics in mechanically ventilated
patients: delivery and response. Crit Care Med 1998; 26(1):31–39. - Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in
Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4(8):519–527. - Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for
the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36(3):737–744. - Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-
associated pneumonia in adults: a randomized trial. JAMA 2003; 290(19):2588–2598. - Cavalcanti M, Valencia M, Torres A. Respiratory nosocomial infections in the medical intensive care
unit. Microbes Infect 2005; 7(2):292–301. - Ioanas M, Ferrer M, Cavalcanti M, et al. Causes and predictors of nonresponse to treatment of
intensive care unit-acquired pneumonia. Crit Care Med 2004; 32(4):938–945. - Bouza E, Munoz P, Burillo A, et al. The challenge of anticipating catheter tip colonization in major
heart surgery patients in the intensive care unit: Are surface cultures useful? Crit Care Med 2005; 33(9):
1953–1960. - Le Conte P, Patel G, Clementi E, et al. [Administration of tobramycin aerosols in patients with
nosocomial pneumonia: a preliminary study]. Presse Med 2000; 29(2): 76–78.
Nosocomial Pneumonia in Critical Care 207